Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GamTBvac in Healthy Volunteers
NCT03255278Phase 1Completed
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of GamTBvac in Tuberculosis (TB) (5 arms). Primary endpoint: The number and severity of adverse effects at 140 Days. Started Jan 2017; status: completed.
02
Drugs
GamTBvac
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03255278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255278.